Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 136 to 150 of 274 results for obesity

  1. Long-term effect of very-low-calorie diets on people with a BMI of 40 kg/m2 or more: What are the long-term effects of using very-low-calorie diets (VLCDs) versus low-calorie diets (LCDs) on weight and quality of life in patients with a body mass index (BMI) of 40 kg/m2 or more, including the impact on weight cycling?

    applicable) Source guidance details Comes from guidance Obesity: identification, assessment and management Number CG189

    Research recommendation
    Published
    30 September 2022

  2. Mandibular advancement splints for severe OSAHS: What is the clinical and cost effectiveness of mandibular advancement splints for managing severe OSAHS?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

    Research recommendation
    Published
    30 September 2021

  3. Mandibular advancement splints for mild symptomatic OSAHS and moderate OSAHS: In mild symptomatic OSAHS, which clinical and physiological phenotypes predict treatment response to customised mandibular advancement splints?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

    Research recommendation
    Published
    30 September 2021

  4. Oxygen therapy for OSAHS: What is the clinical and cost effectiveness of nocturnal oxygen compared with placebo in people with OSAHS who are unable to tolerate CPAP?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

    Research recommendation
    Published
    30 September 2021

  5. Upper airway surgery in people unable to tolerate or adhere to CPAP: What is the clinical and cost effectiveness of upper airway surgical interventions for people with OSAHS who are unable to tolerate or adhere to CPAP?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

    Research recommendation
    Published
    30 September 2021

  6. What is the clinical and cost effectiveness of auto- and fixed-level continuous positive airway pressure (CPAP) for managing moderate and severe OSAHS?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

    Research recommendation
    Published
    30 September 2021

  7. Diabetes mellitus type 1 and type 2: insulin glargine biosimilar (Abasaglar) (ESNM64)

    Summary of the evidence on insulin glargine biosimilar (Abasaglar) for type 1 and type 2 diabetes mellitus to inform local NHS planning and decision-making

    Evidence summary
    Published
    2 December 2015

  8. Treatment for people with COPD–OSAHS overlap syndrome: What is the optimal treatment for people with COPD–OSAHS overlap syndrome: non-invasive ventilation or CPAP?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

    Research recommendation
    Published
    30 September 2021

  9. Auto- versus fixed-level CPAP for OSAHS: What is the clinical and cost effectiveness of auto- and fixed-level continuous positive airway pressure (CPAP) for managing mild obstructive sleep apnoea/hypopnoea syndrome (OSAHS)?

    Comes from guidance Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s Number NG202 Date

    Research recommendation
    Published
    30 September 2021

  10. Hypertension in adults (QS28)

    This quality standard covers managing hypertension in adults. It includes diagnosis and investigations, treatment and specialist referral. It describes high-quality care in priority areas for improvement.

    Quality standard
    Last updated
    1 September 2015
    View quality statements

    Sections for QS28

  11. Type 2 diabetes mellitus in adults: high-strength insulin glargine 300 units/ml (Toujeo) (ESNM65)

    Summary of the evidence on high-strength insulin glargine 300 units/ml (Toujeo) for type 2 diabetes mellitus to inform local NHS planning and decision-making

    Evidence summary
    Published
    2 December 2015

  12. Cerebral palsy in adults (NG119)

    This guideline covers care and support for adults with cerebral palsy. It aims to improve health and wellbeing, promote access to services and support participation and independent living.

    NICE guideline
    Published
    15 January 2019
    View recommendations

    Sections for NG119

  13. PICO negative pressure wound dressings for closed surgical incisions (HTG509)

    Evidence-based recommendations on PICO negative pressure wound dressings for closed surgical incisions.

    HealthTech guidance
    Last updated
    6 August 2019
    View recommendations

    Sections for HTG509

  14. Bipolar disorder, psychosis and schizophrenia in children and young people (QS102)

    This quality standard covers recognition, early intervention and long-term management of bipolar disorder, psychosis and schizophrenia in children and young people (under 18). It also includes support for parents and carers. It describes high-quality care in priority areas for improvement.

    Quality standard
    Published
    15 October 2015
    View quality statements

    Sections for QS102

  15. Further research on robot-assisted kidney transplant should include studies comparing robot-assisted kidney transplant with open surgery. This should collect data on patient selection, warm ischaemia times, the need for conversion to open surgery, graft function, and long-term graft and patient survival.

    kidney transplant is limited in quantity and quality. For patients with obesity who would not otherwise be able to have a kidney...

    Research recommendation
    Published
    21 November 2018